Tech Company Financing Transactions
Serenex Funding Round
Intersouth Partners, Lilly Ventures and Mediphase Venture Partners participated in a $8 million Series B venture round for Serenex. The financing round was announced on 8/3/2004.
Transaction Overview
Company Name
Announced On
8/3/2004
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series B
Investors
Proceeds Purpose
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
323 Foster Street
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Website
Email Address
Not Recorded
Overview
Serenex is an integrated oncology-focused drug discovery and development company. The company's mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Kent
Chief Financial Officer
Ian Howes
Vice President
Judy Bryson
Vice President
Alexander Smith
VP - Bus. Development
Anil Goyal
VP - Operations
George Young
VP - R & D
Steven Hall
Browse more venture capital transactions:
Prev: 8/3/2004: Avera Pharmaceuticals venture capital transaction
Next: 8/4/2004: Kalypsys venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs